PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE

Aim. To study therapeutic equivalence of rosuvastatin generic and original medication and to conduct the pharmacoeconomic analysis to compare the impact of the drug on direct expenses in secondary prevention for the patients with chronic ischemic heart disease (CHD). Material and methods. The open label, prospective observational study performed with the switch of medication, that included 38 patients with chronic CHD and duration of 6 months. During 3 months the patients received original drug rosuvastatin Crestor 10-20 mg, leading to the target level of low density cholesterol